CovidChloroV1, Main, Exploration, bibRecord, 000541

Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.

Identifieur interne : 000541 ( Main/Exploration ); précédent : 000540; suivant : 000542

Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.

Auteurs : Matthieu Million [France] ; Yanis Roussel [France] ; Philippe Gautret [France] ; Didier Raoult [France]

Source :

International journal of antimicrobial agents [ 1872-7913 ] ; 2021.

RBID : pubmed:33408019

Descripteurs français

KwdFr :
- ARN viral (antagonistes et inhibiteurs), ARN viral (génétique), Antibactériens (usage thérapeutique), Antipaludiques (usage thérapeutique), Antiviraux (usage thérapeutique), Association médicamenteuse (MeSH), Azithromycine (usage thérapeutique), Charge virale (effets des médicaments et des substances chimiques), Essais cliniques comme sujet (MeSH), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Partie nasale du pharynx (virologie), RT-PCR (MeSH), Repositionnement des médicaments (MeSH), Statistiques comme sujet (MeSH), Synergie des médicaments (MeSH).
MESH :
- antagonistes et inhibiteurs : ARN viral.
- effets des médicaments et des substances chimiques : Charge virale.
- génétique : ARN viral.
- usage thérapeutique : Antibactériens, Antipaludiques, Antiviraux, Azithromycine, Hydroxychloroquine.
- virologie : Partie nasale du pharynx.
- Association médicamenteuse, Essais cliniques comme sujet, Humains, RT-PCR, Repositionnement des médicaments, Statistiques comme sujet, Synergie des médicaments.

English descriptors

KwdEn :
- Anti-Bacterial Agents (therapeutic use), Antimalarials (therapeutic use), Antiviral Agents (therapeutic use), Azithromycin (therapeutic use), COVID-19 (diagnosis), COVID-19 (drug therapy), COVID-19 (virology), COVID-19 Testing (MeSH), Clinical Trials as Topic (MeSH), Drug Combinations (MeSH), Drug Repositioning (MeSH), Drug Synergism (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Nasopharynx (virology), RNA, Viral (antagonists & inhibitors), RNA, Viral (genetics), Reverse Transcriptase Polymerase Chain Reaction (MeSH), SARS-CoV-2 (drug effects), SARS-CoV-2 (genetics), SARS-CoV-2 (pathogenicity), Statistics as Topic (MeSH), Viral Load (drug effects).
MESH :
- chemical , antagonists & inhibitors : RNA, Viral.
- chemical , genetics : RNA, Viral.
- chemical , therapeutic use : Anti-Bacterial Agents, Antimalarials, Antiviral Agents, Azithromycin, Hydroxychloroquine.
- diagnosis : COVID-19.
- drug effects : SARS-CoV-2, Viral Load.
- drug therapy : COVID-19.
- genetics : SARS-CoV-2.
- pathogenicity : SARS-CoV-2.
- virology : COVID-19, Nasopharynx.
- COVID-19 Testing, Clinical Trials as Topic, Drug Combinations, Drug Repositioning, Drug Synergism, Humans, Reverse Transcriptase Polymerase Chain Reaction, Statistics as Topic.

DOI: 10.1016/j.ijantimicag.2020.106240
PubMed: 33408019
PubMed Central: PMC7779266

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000539
to stream Main, to step Curation: 000539

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.</title>
<author><name sortKey="Million, Matthieu" sort="Million, Matthieu" uniqKey="Million M" first="Matthieu" last="Million">Matthieu Million</name>
<affiliation wicri:level="3"><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roussel, Yanis" sort="Roussel, Yanis" uniqKey="Roussel Y" first="Yanis" last="Roussel">Yanis Roussel</name>
<affiliation wicri:level="3"><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gautret, Philippe" sort="Gautret, Philippe" uniqKey="Gautret P" first="Philippe" last="Gautret">Philippe Gautret</name>
<affiliation wicri:level="3"><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, VITROME, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, VITROME, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Raoult, Didier" sort="Raoult, Didier" uniqKey="Raoult D" first="Didier" last="Raoult">Didier Raoult</name>
<affiliation wicri:level="3"><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France. Electronic address: Didier.raoult@gmail.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33408019</idno>
<idno type="pmid">33408019</idno>
<idno type="doi">10.1016/j.ijantimicag.2020.106240</idno>
<idno type="pmc">PMC7779266</idno>
<idno type="wicri:Area/Main/Corpus">000539</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000539</idno>
<idno type="wicri:Area/Main/Curation">000539</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000539</idno>
<idno type="wicri:Area/Main/Exploration">000539</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.</title>
<author><name sortKey="Million, Matthieu" sort="Million, Matthieu" uniqKey="Million M" first="Matthieu" last="Million">Matthieu Million</name>
<affiliation wicri:level="3"><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roussel, Yanis" sort="Roussel, Yanis" uniqKey="Roussel Y" first="Yanis" last="Roussel">Yanis Roussel</name>
<affiliation wicri:level="3"><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gautret, Philippe" sort="Gautret, Philippe" uniqKey="Gautret P" first="Philippe" last="Gautret">Philippe Gautret</name>
<affiliation wicri:level="3"><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, VITROME, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, VITROME, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Raoult, Didier" sort="Raoult, Didier" uniqKey="Raoult D" first="Didier" last="Raoult">Didier Raoult</name>
<affiliation wicri:level="3"><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France. Electronic address: Didier.raoult@gmail.com.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">International journal of antimicrobial agents</title>
<idno type="eISSN">1872-7913</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Antimalarials (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Azithromycin (therapeutic use)</term>
<term>COVID-19 (diagnosis)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (virology)</term>
<term>COVID-19 Testing (MeSH)</term>
<term>Clinical Trials as Topic (MeSH)</term>
<term>Drug Combinations (MeSH)</term>
<term>Drug Repositioning (MeSH)</term>
<term>Drug Synergism (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Nasopharynx (virology)</term>
<term>RNA, Viral (antagonists & inhibitors)</term>
<term>RNA, Viral (genetics)</term>
<term>Reverse Transcriptase Polymerase Chain Reaction (MeSH)</term>
<term>SARS-CoV-2 (drug effects)</term>
<term>SARS-CoV-2 (genetics)</term>
<term>SARS-CoV-2 (pathogenicity)</term>
<term>Statistics as Topic (MeSH)</term>
<term>Viral Load (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral (antagonistes et inhibiteurs)</term>
<term>ARN viral (génétique)</term>
<term>Antibactériens (usage thérapeutique)</term>
<term>Antipaludiques (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Association médicamenteuse (MeSH)</term>
<term>Azithromycine (usage thérapeutique)</term>
<term>Charge virale (effets des médicaments et des substances chimiques)</term>
<term>Essais cliniques comme sujet (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Partie nasale du pharynx (virologie)</term>
<term>RT-PCR (MeSH)</term>
<term>Repositionnement des médicaments (MeSH)</term>
<term>Statistiques comme sujet (MeSH)</term>
<term>Synergie des médicaments (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>RNA, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>RNA, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Antimalarials</term>
<term>Antiviral Agents</term>
<term>Azithromycin</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>ARN viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS-CoV-2</term>
<term>Viral Load</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Charge virale</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN viral</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term>
<term>Antipaludiques</term>
<term>Antiviraux</term>
<term>Azithromycine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Partie nasale du pharynx</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>COVID-19</term>
<term>Nasopharynx</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19 Testing</term>
<term>Clinical Trials as Topic</term>
<term>Drug Combinations</term>
<term>Drug Repositioning</term>
<term>Drug Synergism</term>
<term>Humans</term>
<term>Reverse Transcriptase Polymerase Chain Reaction</term>
<term>Statistics as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Association médicamenteuse</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>RT-PCR</term>
<term>Repositionnement des médicaments</term>
<term>Statistiques comme sujet</term>
<term>Synergie des médicaments</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33408019</PMID>
<DateCompleted><Year>2021</Year>
<Month>01</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>03</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1872-7913</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>57</Volume>
<Issue>1</Issue>
<PubDate><Year>2021</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>International journal of antimicrobial agents</Title>
<ISOAbbreviation>Int J Antimicrob Agents</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.</ArticleTitle>
<Pagination><MedlinePgn>106240</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0924-8579(20)30459-3</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijantimicag.2020.106240</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Million</LastName>
<ForeName>Matthieu</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Roussel</LastName>
<ForeName>Yanis</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gautret</LastName>
<ForeName>Philippe</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, VITROME, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Raoult</LastName>
<ForeName>Didier</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France. Electronic address: Didier.raoult@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType>
<PublicationType UI="D017418">Meta-Analysis</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Int J Antimicrob Agents</MedlineTA>
<NlmUniqueID>9111860</NlmUniqueID>
<ISSNLinking>0924-8579</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009305" MajorTopicYN="N">Nasopharynx</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>Declaration of Competing Interest The authors declare no competing interests.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year>
<Month>1</Month>
<Day>7</Day>
<Hour>5</Hour>
<Minute>53</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2021</Year>
<Month>1</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33408019</ArticleId>
<ArticleId IdType="pii">S0924-8579(20)30459-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106240</ArticleId>
<ArticleId IdType="pmc">PMC7779266</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2020 May 15;11:1061</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32574262</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2000 Jun 22;342(25):1887-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10861325</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2021 Jan;57(1):106173</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33408016</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Provence-Alpes-Côte d'Azur</li>
</region>
<settlement><li>Marseille</li>
</settlement>
</list>
<tree><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Million, Matthieu" sort="Million, Matthieu" uniqKey="Million M" first="Matthieu" last="Million">Matthieu Million</name>
</region>
<name sortKey="Gautret, Philippe" sort="Gautret, Philippe" uniqKey="Gautret P" first="Philippe" last="Gautret">Philippe Gautret</name>
<name sortKey="Raoult, Didier" sort="Raoult, Didier" uniqKey="Raoult D" first="Didier" last="Raoult">Didier Raoult</name>
<name sortKey="Roussel, Yanis" sort="Roussel, Yanis" uniqKey="Roussel Y" first="Yanis" last="Roussel">Yanis Roussel</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000541 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000541 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:33408019
   |texte=   Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:33408019" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.

Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki